NewsRoom Articles - BioMedWire (BMW)

MondayJun 29, 2026 10:30 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Leverages Epigenetics to Reveal Hidden Heart Disease Risks

Cardio Diagnostics has positioned the science of epigenetics at the center of its diagnostic platform. Looking at an individual person’s epigenetics can provide invaluable insight into the impact of their lifestyle, behavior, and environment. Epigenetics does more than pinpoint a problem, says CEO; it also provides some level of solution. When most people think about their risk for heart disease, they think about family history. Did a parent or grandparent have a heart attack? Is heart disease “in their genes”? It’s an understandable assumption, and genetics does play a role in cardiovascular risk. But a growing body of research suggests…

FridayJun 26, 2026 12:00 pm

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Brings Molecular Precision to a Blind Spot in Coronary Heart Disease (‘CHD’) Detection

For decades, cardiovascular risk assessment has centered on a checklist of factors never designed to capture the full biological picture of how heart disease develops. What makes CHD numbers particularly troubling is that so much of this is preventable. Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics fields that examine how genes are expressed and regulated at the molecular level. Coronary heart disease (“CHD”) remains the leading cause of death in the United States, but the tools doctors have long relied on to detect it early are proving less reliable than many patients assume. Cardio Diagnostics Holdings (NASDAQ:…

FridayJun 26, 2026 10:30 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Before any new drug or diagnostic technology can be used widely, it must pass through a series of structured studies designed to answer specific questions. The milestone highlighted in Quantum BioPharma’s announcement is that patient enrollment in a key pilot study has reached its halfway mark. Preliminary analyses show a robust signal in acute MS lesions, along with potential sensitivity to gray matter lesions. Clinical studies are among the most demanding and consequential undertakings in medicine. They require years of planning, careful patient selection, rigorous data…

FridayJun 26, 2026 10:00 am

US Health Care Expenditure Spiked to Nearly $6 Trillion in 2025

According to recent data released by CMS actuaries, spending on health care in the U.S. jumped to $5.7tn in 2025, the third consecutive year in which spending growth exceeded 7%. The data shows that one of the key drivers of this spike was pricey medications, such as GLP-1s, medications used to treat obesity. CMS actuaries note that this growth in spending stems from a number of factors that include people seeking more care and the uptake of expensive medications like the weight loss drugs mentioned earlier. Cost increases accounted for just a small fraction of this expenditure spike. Jacqueline Fiore, an economist working in the actuarial…

ThursdayJun 25, 2026 10:00 am

Researchers Urge Caution in Using Antibiotic Prophylaxis

The medical community has for long relied on antibiotic prophylaxis, the practice of prescribing antibiotics to safeguard at-risk individuals from bacterial infections. However, a new publication has sounded the alarm on the widespread use of these “just in case” treatments due to their risk of driving antibiotic resistance. The paper, published by researchers at Charles University in Prague, appeared in the Clinical Microbiology & Infection journal. The authors caution that the prophylactic use of antibiotics has become unsustainable due to its growing use by medical practitioners because it threatens the long term efficacy of these medications. As more people use these therapies, the risk of antimicrobial resistance is growing,…

ThursdayJun 25, 2026 9:45 am

Earth Science Tech Inc. (ETST) Presents Fiscal Year-End Financial Results for March 31, 2026, Operating a Diversified Holding Company Model

Earth Science Tech Inc. (OTC: ETST) recently reported year-end financial results for the fiscal year ending March 31, 2026 Earth Science Tech acquires, manages, and operates companies in pharmaceuticals, real estate, telemedicine, healthcare services, and other industries. Results include increases in revenue, gross profit, net income, and total assets. Earth Science Tech (OTC: ETST), a strategic holding company that acquires and manages a diverse portfolio of businesses, recently announced the financial results for the full fiscal year that ended on March 31, 2026 (https://ibn.fm/xRoIz). The reported results include: An 8% revenue increase compared to the year ended March 31, 2025,…

WednesdayJun 24, 2026 11:15 am

VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline

VERAXA Biotech has reported new in vitro proof-of-concept data supporting its BiTAC-ADC technology, demonstrating selective activity against cancer cells while sparing healthy cells in early testing. The company is presenting its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations at the BIO International Convention 2026. VERAXA’s proprietary BiTAC approach is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells. The company maintains a diversified oncology pipeline of antibody-based formats including antibody-drug conjugates (“ADCs”), T-cell engagers (“TCEs”), and other antibody-based formats. VERAXA recently began trading on the NASDAQ Capital Market under the…

WednesdayJun 24, 2026 10:30 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF): Cancer Nanomedicine Enters a New Generation

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. Cancer nanomedicine is emerging from an early period of skepticism, with more than 20 approved formulations now improving therapeutic index and patient quality of life during treatment Onco-Innovations’ lead drug candidate, ONC010, pairs a small-molecule PNKP inhibitor with a polymer nanodelivery system designed to extend circulation, increase drug retention in tumor, and improve tolerability Recent manufacturing updates, including kilogram-scale precursor production and a proposed Nanosoft Polymers collaboration, point to a sharpening focus on scalability, reproducibility, and regulatory readiness ahead of first-in-human studies For decades, chemotherapy has…

WednesdayJun 24, 2026 9:00 am

The Quest to Repair What Multiple Sclerosis Takes Away

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently living with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions of MS sufferers. Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (Profile) is determined working to change that…

WednesdayJun 24, 2026 9:00 am

Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market

BioMedWire Editorial Coverage: Oncology research is moving through one of its most active stretches in years. DNA Damage Response (“DDR”) inhibitors, a category of drugs that work by blocking cancer cells' capacity to fix their own damaged DNA, are growing well beyond the poly ADP ribose polymerase (“PARP”) inhibitor that first defined the category. DDR-inhibiting therapies generated an estimated $7 billion-plus in worldwide sales in 2025, and the wider oncology, diagnostics and precision medicine markets are expected to approach about $750 billion by 2030. A fresh wave of inhibitor classes is now taking shape as the next major opportunity. Standing at…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Leverages Epigenetics to Reveal Hidden Heart Disease Risks

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Brings Molecular Precision to a Blind Spot in Coronary Heart Disease (‘CHD’) Detection

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study

US Health Care Expenditure Spiked to Nearly $6 Trillion in 2025

Researchers Urge Caution in Using Antibiotic Prophylaxis

Earth Science Tech Inc. (ETST) Presents Fiscal Year-End Financial Results for March 31, 2026, Operating a Diversified Holding Company Model

VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF): Cancer Nanomedicine Enters a New Generation

The Quest to Repair What Multiple Sclerosis Takes Away

Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search